Top

Sleep and Breathing

Published in:

01-09-2010 | Original Article

Impact of CPAP treatment on cardiac biomarkers and pro-BNP in obstructive sleep apnea syndrome

Authors: Nilüfer Çifçi, Meral Uyar, Osman Elbek, Hüseyin Süyür, Erhan Ekinci

Published in: Sleep and Breathing | Issue 3/2010

Abstract

Objective

To evaluate the effect of continuous positive airway pressure (CPAP) therapy on pro-brain natriuretic peptide (BNP) and cardiac markers in patients with obstructive sleep apnea syndrome and normal cardiac function.

Methods

Thirty-three consecutive patients with sleep apnea syndrome were analysed for serum pro-BNP and cardiac markers prior to and after 6 months of CPAP therapy.

Results

Twenty five patients had normal (83.3%) while remaining five (16.7%) revealed high pro-BNP values. We did not detect any significant difference between severity of obstructive sleep apnea syndrome and serum pro-BNP levels (p = 0.534). A statistically significant difference was not observed between basal and sixth-month creatine kinase (CK), creatine kinase-MB (CK-MB), troponin I, pro-BNP, aspartate transaminase (AST), and CK levels in patients with sleep apnea syndrome (p > 0.05).

Conclusion

Obstructive sleep apnea syndrome does not induce myocardial damage enough to increase serum pro-BNP, CK, CK-MB, troponin I, and AST levels. Markers sensitive to ischemia could be preferred to evaluate effect of obstructive sleep apnea syndrome.

Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350:655–663CrossRefPubMed

Hukins CA (2006) Obstructive sleep apnea—management update. Neuropsychiatr Dis Treat 3:309–326CrossRef

Goetze JP, Friis-Hansen L, Rehfeld JF, Nilsson B, Svendsen JH (2006) Atrial secretion of B-type natriuretic peptide. Eur Heart J 27:1648–1650CrossRefPubMed

Grabowski M, Filipiak KJ, Karpinski G, Wretowski D, Rdzanek A, Huczek Z, Horszczaruk GJ, Kochman J, Ruduwski R, Opolski G (2004) Serum B-type natriuretic peptide levels on admission predict not only short term death but also angiographic success of procedure in patients with acute ST-elevation myocardial infarction treated with primary angioplasty. Am Heart J 148:655–662CrossRefPubMed

Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Trouqhton RW, Elliott J, Frampton C, Turner J, Crozier IG, Yandle TG (2003) B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107:2786–2792CrossRefPubMed

Kaneko Y, Floras JS, Usui K, Plante J, Tkacova R, Kubo T, Ando S, Bradley TD (2003) Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 348:1233–1241CrossRefPubMed

Anwaruddin S, Januzzi JL Jr, Baggish AL, Lewandrowski EL, Lewandrowski KB (2005) Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol 123:140–145CrossRefPubMed

Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W (2006) American society of echocardiography's nomenclature and standards committee; task force on chamber quantification; American college of cardiology echocardiography committee; American heart association; European association of echocardiography. European society of cardiology. Recommendations for chamber quantification. Eur J Echocardiog 7:79–108CrossRef

American Academy of Sleep Medicine (1999) Sleep related breathing disorders in adults: recommendations for syndrome definition techniques in clinical research. The report of an American Academy of Sleep Medicine Task force. Sleep 22:667–689

10.

Butt M, Dwivedi G, Khair O, Lip GY (2009) Obstructive sleep apnea and cardiovascular disease. Int J Cardiol (epub ahead of print)

11.

McNicholas WT, Bonsigore MR, Management Committee of EU COST ACTION B26 (2007) Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 29:156–178CrossRefPubMed

12.

Maeder MT, Ammann P, Rickli H, Schoch OD, Korte W, Hürny C, Myers J, Münzer T (2008) N-terminal pro-B-type natriuretic peptide and functional capacity in patients with obstructive sleep apnea. Sleep Breath 12:7–16CrossRefPubMed

13.

Kaditis AG, Alexopoulos EI, Hatzi F, Kostadima E, Kiaffas M, Zakynthinos E (2006) Overnight change in brain natriuretic peptide levels in children with sleep-disordered breathing. Chest 130:1377–1384CrossRefPubMed

14.

Zhao ZH, Liu ZH, Luo Q, Xiong CM, Ni XH, Zhang J, Zhang S, Yang YJ (2006) Positive pressure ventilation treatment reduces plasma levels of amino terminal-probrain natriuretic peptide in congestive heart failure patients with sleep apnea. Circ J 70:572–574CrossRefPubMed

15.

Kita H, Ohi M, Chin K, Noquchi T, Otsuka N, Tsuboi T, Itoh H, Nakao K, Kuno K (1998) The nocturnal secretion of cardiac natriuretic peptides during obstructive sleep apnoea and its response to therapy with nasal continuous positive airway pressure. J Sleep Res 7:199–207CrossRefPubMed

16.

Hubnera RH, El Mokhtarib NE, Freitag S, Rauscheb T, Goderd R, Tirokeb A (2008) NT-proBNP is not elevated in patients with obstructive sleep apnoea. Respir Med 102:134–142CrossRef

17.

Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R (2005) N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352:666–675CrossRefPubMed

18.

Gami AS, Svatikova A, Wolk R, Olson EJ, Duenwald CJ, Jaffe AS, Somers VK (2004) Cardiac troponin T in obstructive sleep apnea. Chest 125:2097–2100CrossRefPubMed

Title: Impact of CPAP treatment on cardiac biomarkers and pro-BNP in obstructive sleep apnea syndrome
Authors: Nilüfer Çifçi
Meral Uyar
Osman Elbek
Hüseyin Süyür
Erhan Ekinci
Publication date: 01-09-2010
Publisher: Springer-Verlag
Published in: Sleep and Breathing / Issue 3/2010
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI: https://doi.org/10.1007/s11325-009-0306-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2010

Changes of hematocrit and hemoglobin concentration in the cold Himalayan environment in dependence on total body fluid

Pneumothorax as an initial manifestation of obstructive sleep apnea syndrome

Hypoxia: good guy or bad guy?

19th Annual Meeting of the American Academy of Dental Sleep Medicine, San Antonio, Texas, USA, 4–6 June 2010

American academy of dental sleep medicine continuing education offerings

Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials